An Epidemiologic Evaluation of Adverse Events of 5-Alpha-Reductase Inhibitors

5-α-还原酶抑制剂不良事件的流行病学评估

基本信息

  • 批准号:
    8916105
  • 负责人:
  • 金额:
    $ 10.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We propose a harmacoepidemiologic study of 5-alpha-reductase inhibitors (5ARIs) to address emerging safety concerns (permanent sexual side effects, depression) with use of these marketed drugs, presently being considered for expanded use in healthy men as agents of prostate cancer chemoprevention. In order to cost- efficiently deliver needed safety information, this research will examine the occurrence of adverse events (AEs) via analysis of a large electronic medical records database, the UK-based Clinical Practice Research Datalink (CPRD). The CPRD is the most widely-used resource for pharmacoepidemiologic research in the world. In preliminary analyses of this very large database (11M patients, 45M patient-years), we have identified over 58,000 users of the drug class in question with on average approximately 10 years of follow-up time. In addition to studying risk of events, the proposed study will be the first to study symptom persistence in relation to both types of drugs in the class (finasteride and dutasteride), and will be the largest epidemiologic study of its kind to date. We propose to examine the occurrence of 4 thematic groups of AEs: 1) erectile dysfunction (ED); 2) non- ED sexual dysfunction (ejaculatory and psychosexual dysfunction, low libido, Peyronie's disease); 3) breast outcomes (benign/malignant breast diseases), and 4) depression, using longitudinal epidemiologic approaches. In addition to a retrospective cohort study focused on incident events, we will examine the persistence/permanency of sexual dysfunction outcomes and depression following drug cessation, and risk factors for permanency. Our analyses are designed such that men under various drug treatments for benign prostatic hyperplasia (BPH) are compared (finasteride, dutasteride, and alpha-blockers) to account for the underlying influence of BPH on outcomes. We will examine potential confounding in our analysis using the wide variety of medical and behavioral factors available in CPRD, including use of novel methods such as high-dimensional propensity score analysis. Our research team is comprised of experts in the epidemiology of male aging, pharmacoepidemiology relating to sexual function and lower urinary tract symptoms, and clinical treatment of BPH. The PI has immediate access and >25 years of experience in pharmacoepidemiologic utilization of the CPRD. Other strengths of our proposed study include its large size, use of medical records (avoiding the need to rely on patient recall o prescriptions and avoidance of problems with use of medical claims), longitudinal design, the ability to compare 5ARIs to other treatments, and the richness of the underlying dataset for confounder control. The public health contribution of the study is to quickly to inform the safety profile of the 5ARI class for currently-approved indications before further expansion to healthy men for chemoprevention.
描述(由申请方提供):我们提出了一项5-α-还原酶抑制剂(5ARI)的药物流行病学研究,以解决使用这些市售药物时出现的安全性问题(永久性副作用、抑郁),目前正在考虑在健康男性中作为前列腺癌化学预防药物扩大使用。为了经济高效地提供所需的安全性信息,本研究将通过分析大型电子病历数据库(英国临床实践研究数据链(CPRD))来检查不良事件(AE)的发生率。CPRD是世界上最广泛使用的药物流行病学研究资源。在对这个非常大的数据库(1100万患者,4500万患者-年)的初步分析中,我们已经确定了超过58,000名相关药物类别的使用者,平均随访时间约为10年。除了研究事件的风险外,拟议的研究将是第一个研究与该类药物(非那雄胺和度他雄胺)有关的症状持续性的研究,也是最大的研究。 迄今为止的流行病学研究。 我们建议使用纵向流行病学方法检查4组主题AE的发生率:1)勃起功能障碍(艾德); 2)非艾德性功能障碍(射精和性心理功能障碍、性欲低下、佩罗尼氏病); 3)乳腺结局(良性/恶性乳腺疾病)和4)抑郁症。除了一项针对偶发事件的回顾性队列研究外,我们还将研究停药后性功能障碍结局和抑郁的持续性/永久性,以及永久性的风险因素。我们的分析旨在比较接受各种药物治疗良性前列腺增生(BPH)的男性(非那雄胺、度他雄胺和α-受体阻滞剂),以解释BPH对结局的潜在影响。我们将使用CPRD中可用的各种医学和行为因素,包括使用高维倾向评分分析等新方法,检查分析中的潜在混杂因素。 我们的研究团队由男性衰老流行病学、与性功能和下尿路症状相关的药物流行病学以及BPH临床治疗方面的专家组成。PI可直接访问CPRD,并具有>25年的药物流行病学使用经验。我们提出的研究的其他优势包括其规模大,使用医疗记录(避免需要依赖患者回忆处方和避免使用医疗索赔的问题),纵向设计,将5ARI与其他治疗进行比较的能力,以及混淆控制的基础数据集的丰富性。该研究的公共卫生贡献是在进一步扩展到健康男性进行化学预防之前,快速告知5ARI类药物用于当前批准适应症的安全性特征。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hozefa Divan其他文献

Hozefa Divan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 10.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 10.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了